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Abstract: We performed a genome-wide association study (GWAS) to identify genetic variation
associated with common forms of idiopathic generalized epilepsy (GE) and focal epilepsy (FE). Using
a cohort of 2220 patients and 14,448 controls, we searched for single nucleotide polymorphisms
(SNPs) associated with GE, FE and both forms combined. We did not find any SNPs that reached
genome-wide statistical significance (p ≤ 5 × 10−8 ) when comparing all cases to all controls, and few
SNPs of interest comparing FE cases to controls. However, we document multiple linked SNPs
in the PADI6-PADI4 genes that reach genome-wide significance and are associated with disease
when comparing GE cases alone to controls. PADI genes encode enzymes that deiminate arginine
to citrulline in molecular pathways related to epigenetic regulation of histones and autoantibody
formation. Although epilepsy genetics and treatment are focused strongly on ion channel and
neurotransmitter mechanisms, these results suggest that epigenetic control of gene expression and
the formation of autoantibodies may also play roles in epileptogenesis.
Keywords: epilepsy; human genetics; association study
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1. Introduction
Epilepsy is an umbrella term for a heterogeneous group of diseases that involve
recurring seizures of many varieties as well as associated comorbidities. It is one of the most
common of neurological illnesses, with a global incidence of 0.3–1.7% [1]. Although
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epilepsy incidence does not vary based on geography, culture or sex, it has nonetheless
been difficult to estimate worldwide incidence due to socioeconomic variables between
low- and high-income countries [2].
Some forms of epilepsy are rare, caused by a single gene mutation inherited in a predictable Mendelian pattern [3]. However, the vast majority of patients suffer from epilepsy
subtypes of unknown etiology. These include both generalized epilepsies (GE, also called
genetic generalized epilepsies: GGE) such as juvenile myoclonic epilepsy (JME) or childhood
absence epilepsy (CAE), as well as focal epilepsies (FE) including temporal lobe epilepsy (TLE)
with or without mesial temporal sclerosis (MTS). These common forms present as complex
traits with no clear mode of inheritance, suggesting that they are caused by multiple genetic
variants interacting with environmental influences [3]. Genome-wide association studies
(GWAS) have been used to identify specific genetic variants that influence the etiology of
many complex human traits and, in recent years, GWAS have successfully identified factors
contributing to common illnesses [4]. Documenting an association between a common disease
and common genetic variations (i.e., those occurring in >1% of chromosomes tested) opens
new avenues of research into pathophysiological mechanisms.
To date, five epilepsy GWAS have been published. The first included cohorts of patients from Europe, USA and the UK who were diagnosed as having FE from both unknown
and known causes, the latter including conditions such as infection, tumor or trauma [5].
No single nucleotide polymorphisms (SNPs) reached the conventionally accepted threshold
for declaring genome-wide statistical significance (p < 5 × 10−8 ) [5]. There were several
regions harboring SNPs that gave suggestive association (5 × 10−8 < p < 5 × 10−6 ) and it is
likely that there were multiple false-negative (i.e., true-positive) loci represented within
this level of statistical noise [4]. The second GWAS examined patients from China with FE,
again including cases of both known and unknown cause [6]. In this study, only one variant,
an SNP within CAMSAP1L1 on 1q32, reached genome-wide significance (p = 1 × 10−8 ) [6].
The third epilepsy GWAS examined patients of European ancestry with idiopathic GE,
including presumed genetic absence epilepsy (GAE), CAE, juvenile absence (JAE) and
JME (EPICURE Consortium; EMINet Consortium) [7]. The patients were separated into
two cohorts, one for discovery and one for replication, and a two-stage statistical analysis
approach was employed. No SNPs reached genome-wide significance in the discovery
cohort when GE, GAE or JME were compared individually to controls. However, when
the replication cohort was processed and both datasets were combined by a meta-analysis,
there were several chromosomes where markers reached genome-wide significance, including regions on 2p16.1 and 17q21.32 for GE, 2q22.3 for GAE and 1q43 for JME; in addition,
there was a region of suggestive association at 2q24.3 for GE [7]. Next, a meta-analysis of
prior GWAS [5,7], as well as the patients from this present study and other cohorts from
different groups, was published under the auspices of the International League Against
Epilepsy (ILAE) led by a Consortium on Complex Epilepsies [8]. This latter report included
8696 epilepsy patients and 26,157 controls and, compared to prior published work, it used
a more stringent statistical criterion to declare genome-wide significance (p < 1.66 × 10−8 ).
Results from the comparison between all patients with epilepsy and all control individuals revealed a number of genome-wide significant SNPs at 2q24.3 (p = 8.71 × 10−10 ),
implicating SCN1A (a sodium ion channel subunit gene), and at 4p15.1 (p = 5.44 × 10−9 ),
implicating PCDH7 (a protocadherin gene). In the ILAE meta-analysis of the GE cohort,
a single SNP at 2p16.1 (p = 9.99 × 10−9 ) was identified, most strongly implicating VRK2 or
FANCL. In addition, a statistical signal was detected at multiple SNPs in the MMP8 locus
on 11q22.2 (p < 2.37 × 10−8 ). The meta-analysis did not detect any SNPs that achieved
genome-wide significance in the FE cohort. Most recently, the ILAE reported on an updated
cohort that contained 15,212 patients and 29,677 controls, identifying 11 novel variations
that reached genome-wide significance in the GE cohort and variants associated with all
epilepsies, as well as with FE specifically [9].
Here, we report a GWAS on our cohort of patients we designate as the “Philadelphia
Cohort”. The patients are all from North America and have common forms of GE and
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FE (see Materials and Methods). Our study results identify novel genetic loci that are
potentially involved in the pathogenesis of epilepsy and that may provide entry points into
novel pathways for possible therapeutic intervention [1].
2. Materials and Methods
2.1. Study Subjects
All subjects, including patients and controls, completed the informed consent process
approved by local Institutional Review Boards at participating clinical sites. Peripheral
blood samples were the preferred method for DNA sampling, but saliva samples were
collected for some pediatric cases. Clinical inclusion criteria for GE and FE have been
published previously [10]. These inclusion criteria give diagnostic age ranges for each
of the epilepsy types collected and the cohorts have roughly equal distributions of male
and female subjects. This cohort consisted of 2220 patients and 14,488 controls with
964 focal cases and 827 generalized cases collected directly by participating sites. Approximately 80% of the samples came from Jefferson, The Children’s Hospital of Philadelphia
(CHOP) and Nationwide Children’s Hospital, with 20% coming from the remaining four
sites (University of Pennsylvania, University of Cincinnati, University of Montreal and
MGH/Harvard/Beth Israel Deaconess). Another 429 samples were added via screening of
electronic health records from CHOP. Controls were also recruited at individual clinical
sites with the majority (>95%) coming from the DNA repository at the Center for Applied Genomics (CAG) at CHOP. Case and controls were matched by ancestry and GWAS
analysis used sex as a covariant.
2.2. Ethical Approval Code
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol
was approved by the Ethics Committee of each participating institution under the overall auspices of the Institutional Review Board at Thomas Jefferson University Hospital
(protocol #10F.208 approved 11 July 2019).
2.3. Overview: Genome-Wide Association Meta-Analysis
For gene discovery, we utilized cohorts in which the majority of cases were collected
specifically for genetic studies and were recruited through epilepsy specialty physicians.
We collected a smaller number of subjects via identification from the electronic medical
record (EMR). To qualify for inclusion as a GE or FE case via EMR, an individual had to have
an ICD9 code specifying that specific subtype of epilepsy (e.g., 345.1 or 345.4) and had to
have been seen by a neurologist confirming the diagnosis (of GE or FE). All other ICD9 code
diagnoses that pointed to idiopathic epilepsy were included in the ‘all epilepsy’ category.
Table 1 presents information on patient ancestry, data acquisition chip used for genotyping
and the type of epilepsy (GE or FE). For patients of European and African ancestries,
we used METAL meta-analysis on cohorts 1, 3, and 5 and 2, 4 and 6, respectively [11].
All cases were matched with controls that were genotyped on the same platform with
similar proportions of each cohort typed on each of the 3 platforms. For the combined
European and African ancestry trans-ethnic meta-analysis, we utilized MANTRA and
a Baysian approach [12].
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Table 1. Epilepsy cohorts.

Phenotyping
Genotyping Platform
Race
Patient categories/numbers
analyzed
All Epilepsy
Focal Epilepsy
Generalized Epilepsy
Controls

Cohort 1

Cohort 2

Cohort 3

Cohort 4

Cohort 5

Cohort 6

Physician
verified
550v1, 550v3,
610
European
American

Physician
verified
550v1, 550v3,
610
African
American

Physician
verified

Physician
verified

OmniExpress

OmniExpress

European
American

African
American

Electronic
Medical Record
550v1, 550v3,
610
European
American

Electronic
Medical Record
550v1, 550v3,
610
African
American

819
378
440
5736

159
92
67
2746

483
287
190
682

106
61
44
97

432
91
54
3443

221
55
32
1784

2.4. Meta-Analysis: METAL and MANTRA
The genome-wide analyses of the European and Africa ancestry cohorts were metaanalyzed separately using METAL. MANTRA was then used for trans-ethnic meta-analysis.
Sample numbers used are shown in Table 1. A total of 2220 epilepsy patient samples
passed quality control and were included in the analysis. Of these, 964 were FE, 827
were GE and an additional 429 were from electronic records and not categorized as GE
or FE. The control group consisted of 14,488 samples that passed all quality controls for
genotyping. Statistical significance was set at genome-wide p ≤ 5 × 10−8 for METAL
analysis. Statistical significance was set at Bayes Factor ≥ 6.00 for the MANTRA analysis.
2.5. Genotyping
We performed high-throughput genome-wide genotyping using three different highdensity SNP arrays. Samples included in the discovery phase of the analysis were genotyped on the Illumina Infinium HumanHap550, Human610-Quad and HumanOmniExpress platforms.
2.6. Ancestry Determination
Data were pre-filtered for sample call rate > 95%, SNP call rate > 95% and minor allele
frequency > 1%. The genotypes were then combined with those derived from overlapping
SNPs within HapMap Phase 3. The Genome-wide Complex Trait Analysis (GCTA) program
was used to determine the eigenvalues and eigenvectors of the samples [13]. The resulting
top 10 eigenvectors were then used as input for a k-nearest neighbor‘s algorithm, which
was trained on the Hapmap Phase 3 samples and their respective ancestries. The samples
were then classified as the ancestry of the nearest Hapmap Phase 3 neighbor. The ‘knn’
function in the ‘class’ package in R was used for the k-nearest neighbor classification algorithm (https://stat.ethz.ch/R-manual/R-devel/library/class/html/knn.html) (accessed
on 21 May 2017).
2.7. Imputation
Prior to imputation, samples were only retained in the analysis if they had either
European or African ancestry, as these racial groups were the only ones of appropriate
sample size. Samples were then grouped into their respective cohorts. Cohorts in which
there were multiple BeadChip types were only analyzed with the subset of SNPs common
to the different BeadChip types. Samples were then retained only if they had a sample
call rate > 95% and were estimated to have an identity-by-descent proportion < 0.1875
with any other sample. SNPs were retained if they had a call rate > 95%, minor allele
frequency > 1% and Hardy–Weinberg equilibrium (HWE) p > 1 × 10−6 . All quality control
was performed using PLINK [14]. All SNP positions are based on hg19 build. Samples
were then pre-phased and genotypes imputed with the 1000 Genome phase 1 Interim
haplotypes using Impute v2 [15]. Cases and controls were genotyped on different chip
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platforms, and all were matched to the appropriate chip and imputation data for final
analyses (see Table 1).
2.8. SNP Validation
In order to test the accuracy of imputation, we selected a subset of cases and controls
for Sanger sequencing using rs36067110 on 1p36.13 as a representative SNP. The forward
sequencing primer was 50 -CTGTGCCTGGCCATATCATCT-30 and the reverse sequencing
primer was 50 -CCGTTGGTGGTAGGTGTCTAA-30 .
2.9. Genome-Wide Association
Prior to association analyses, SNPs were removed from the dataset if they had an info
value < 0.8, minor allele frequency < 1% or HWE p < 1 × 10−6 . All remaining SNPs
were tested by logistic regression using the top 3 eigenvectors and sex as covariates for
the 3 phenotypes. We used SNPtest for the association analysis (https://mathgen.stats.ox.
ac.uk/genetics_software/snptest/snptest.html) (accessed on 21 May 2017).
2.10. Meta-Analysis
The cohorts separated by ancestry were meta-analyzed using METAL applying an inverse variance-based algorithm [15]. SNPs were removed from the meta-analysis if they had
a heterogeneity (p < 0.05 or I2 < 50) or were missing from one of the groups for quality control reasons. Individual study- and meta-analysis-level genomic control was used prior to
calculation of final ancestry-specific meta-analysis statistics. An SNP in the ancestry-specific
meta-analysis was considered to be genome-wide significant with a p-value ≤ 5 × 10−8 .
Ancestry-level meta-analysis statistics were then combined using MANTRA in a transethnic meta-analysis. The number of samples in each analysis was calculated as the effective
sample size Neff = 4/(1/Ncases + 1/Nctrls ). An SNP in the trans-ethnic meta-analysis was
considered to be genome-wide significant with a log10 (Bayes Factor) ≥ 6.
3. Results
3.1. METAL and MANTRA for All Epilepsy Patients vs. All Controls
When comparing all patients to all controls, no SNPs reached the threshold for statistical significance in either METAL or MANTRA analyses.
3.2. METAL for Patients of European Ancestry with GE
Table 2 shows that three SNPs reached genome-wide significance (p < 5 × 10−8 )
in the METAL analysis. The markers are located at 1p36.13 in the PADI4-PADI6 locus.
Furthermore, six additional SNPs in this region reached p-values of 5.3–8.1 × 10−8 , resulting
in nine linked markers with p-values between 10−7 and 10−8 . These data document
a positive association between variants in PADI6-PADI4 and GE in European subjects.
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Table 2. METAL and MANTRA analyses for generalized epilepsy.
METAL
AFRICAN

EUROPEAN

MANTRA

SNP

CHR

p-Value

β

p-Value

β

Bayes Factor

Gene

rs5928634
rs5927306
rs71644049
17-77865302
rs71644048
rs36067110
rs34199675
rs34871124
rs79100767
rs71644042
rs34018214
rs113755744
rs79351721
rs4609339
rs35240185
4-64069300

23
23
1
17
1
1
1
1
1
1
1
5
22
23
1
4

0.000005
0.000005
NA
NA
NA
NA
NA
NA
NA
NA
NA
6.22 × 10−8
8.30 × 10−8
0.00004
NA
0.9

0.75
−0.75
NA
NA
NA
NA
NA
NA
NA
NA
NA
−2.55
−1.76
0.65
NA
0.02

0.00005
0.00005
2.93 × 10−8 *
3.98 × 10−8 *
3.05 × 10−8 *
2.86 × 10−8 *
5.31 × 10−8
5.41 × 10−8
8.12 × 10−8
5.99 × 10−8
1.70 × 10−8 *
NA
NA
0.00005
7.88 × 10−8
7.8 × 10−9

0.22
−0.22
−1.49
1.36
−1.31
1.39
−1.33
−1.33
1.27
1.31
1.42
NA
NA
0.22
1.27
−1.97

6.39 *
6.23 *
6.21 *
6.16 *
6.15 *
6.02 *
5.99
5.98
5.75
5.73
5.72
5.72
5.71
5.71
5.70
4.80

near TMEM47
near TMEM47
PADI6 intron
none
PADI6 intron
PADI6 intron
PADI4 intron
PADI4 intron
PADI4 intron
PADI4 intron
PADI4 intron
none
HPS4
near TMEM47
PADI4 syn
near TECRL

* statistically significant for METAL (p ≤ 5 × 10−8 ) or MANTRA (Bayes ≥ 6.00). β represents the log of the odds ratio. A positive β is
an odds ratio greater than 1 and represents a susceptibility allele. Conversely, a negative β is an odds ratio less than 1 and represents
a resistance allele.

3.3. METAL for GE in Patients of African Ancestry
Table 2 shows that no SNPs reached genome-wide significance when comparing
patients of African ancestry with GE to controls. However, suggestive p values (~10−5 )
were found at three linked markers on the X chromosome near TMEM47, as was also found
for patients of European ancestry.
3.4. MANTRA for GE Trans-Ethnic Analysis
Table 2 shows the results of the MANTRA analysis on all patients with GE. These data
support the METAL analysis of European patients with GE, as the same three PADI6
SNPs that reach genome-wide significance in the METAL analysis also reach genome-wide
significance in the Bayes analysis, with Bayes Factors between 6.02 and 6.21. Two additional
markers in PADI4 reached Bayes Factors of 5.99 and 5.98. Four more SNPs in PADI4 reached
Bayes factors between 5.71 and 5.75. These data confirm a strong association between GE
and PADI4-PADI6.
In the METAL analysis, the association between GE and SNPs on the X chromosome
near TMEM47 gave a p-value of 10−5 for patients of both European and African ancestry.
Combined ancestry data with MANTRA show that two of these markers reach genomewide significance (rs5928634, Bayes = 6.39 and rs5927306 Bayes = 6.23). One SNP on
chromosome 17 reached a statistically significant Bayes Factor of 6.16 with a METAL pvalue in Europeans of 3.98 × 10−8 ); however, this is a lone marker in a gene poor region
and most likely represents a false-positive result.
3.5. METAL for FE Patients of European Ancestry
Table 3 shows the results of METAL analysis for the cohort of European FE patients.
Only one marker, on the X chromosome (X-73537149) in MAP2K4P1, reached METAL
significance in FE patients of European ancestry (p = 2.45 × 10−8 ). Once again, this lone
marker, which is in a pseudo-gene, most likely represents a false-positive signal.
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Table 3. METAL and MANTRA analyses for focal epilepsy.
METAL
AFRICAN
SNP
rs12554609
19-5961503
X-73537149
rs114591251
rs58069848
18-41994464
18-42005131
rs116831532
18-42008808
rs12499431
rs117507875
rs114818774
18-41998414
18-42005556
18-42004210
rs114184892
rs113055513
18-41991735
18-42008321
X-51313775

CHR
9
19
23
19
2
18
18
18
18
4
18
18
18
18
18
18
4
18
18
X

p-Value
10−9

1.08 ×
*
2.15 × 10−8 *
NA
3.66 × 10−8 *
3.83 × 10−8 *
5.19 × 10−8
6.14 × 10−8
5.11 × 10−8
6.97 × 10−8
5.68 × 10−8
6.33 × 10−8
6.93 × 10−8
5.48 × 10−8
6.20 × 10−8
5.07 × 10−8
6.55 × 10−8
1.27 × 10−7
5.09 × 10−8
1.24 × 10−7
4.03 × 10−8

EUROPEAN

MANTRA

β

p-Value

β

Bayes Factor

Gene

−2.06
2.25
NA
−2.08
2.02
1.68
−1.67
1.68
1.66
2.30
−1.67
−1.66
−1.68
−1.68
−1.68
−1.66
2.28
1.68
1.62
1.05

NA
NA
2.45 × 10−8 *
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

NA
NA
1.04
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

7.25 *
6.30 *
6.29 *
6.15 *
6.13 *
5.99
5.95
0.95
5.95
5.94
5.89
5.89
5.88
5.87
5.87
5.85
5.71
5.68
5.65
4.67

ASS1 intron
RANBP3
MAP2K4P1
RANBP3
none
PIKC3
PIKC3
PIKC3
PIKC3
SMARCA5
PIKC3
PIKC3
PIKC3
PIKC3
PIKC3
PIKC3
SMARCA5
PIKC3
PIKC3
near NUDT10

* statistically significant for METAL (p ≤ 5 × 10−8 ) or MANTRA (Bayes ≥ 6.00). β represents the log of the odds ratio. A positive β is
an odds ratio greater than 1 and represents a susceptibility allele. Conversely, a negative β is an odds ratio less than 1 and represents
a resistance allele.

3.6. METAL for Patients of African Ancestry with FE
Table 3 shows the results of METAL analysis for the cohort of African patients with
FE. Overall, four SNPs reached genome-wide significance; however, only two were linked
and found in the same gene, RANBP3, on chromosome 19 (rs114591251, p = 3.66 × 10−8
and 19-5961503, p = 2.15 × 10−8 ). The other two are single markers, one in the ASS1 gene
on chromosome 9 and another in a gene poor region of chromosome 2 (rs12554609 in ASS1,
p = 1.08 × 10−9 , and rs58069848, p = 3.82 × 10−8 ).
3.7. MANTRA for FE Trans-Ethnic Analysis
Table 3 shows the results of the MANTRA trans-ethnic analyses for all patients with
FE. Interestingly, for this cohort, the analysis calculated genome-wide significance for
the single marker in ASS1 noted above (Bayes 7.2) and the two linked SNPs in RANBP3
also noted above (Bayes = 6.30 and 6.15, respectively). The lone marker in MAP2K4P1
that reached genome-wide significance in the European FE METAL analysis is also statistically significant in MANTRA (Bayes = 6.29). The lone marker in the gene-poor region
of chromosome 2 also shows a statistically significant MANTRA signal (Bayes = 6.13).
In addition, the MANTRA results provide evidence for a suggestive association at 18q12.3
in the PIK3C3 locus. Two SNPs in this region are very close to the threshold for genomewide significance with Bayes factors at 5.99 and 5.96. Seven additional SNPs in this locus
had Bayes factors between 5.65 and 5.94, and p-values in the African cohort via METAL
that ranged from 1.2 × 10−7 to 5.1 × 10−8 . These combined data provide evidence for
a suggestive association between FE and PIK3C3. Further study of this locus is warranted,
especially in patients of African ancestry.
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4. Discussion
We report positive results from a GWAS in common forms of epilepsy utilizing
patients exclusively from the Philadelphia Cohort, samples that were included as part
of a global (and ongoing) ILAE project [8,9]. In the present study, a set of nine linked
markers in the PADI4-PADI6 locus reach genome-wide or near genome-wide levels of
statistical significance in patients with GE of European ancestry. Although this is a low
yield, it is consistent with prior epilepsy GWAS using individual or a small number of
patient cohorts [5–7].
Follow-up studies on larger patient populations assembled by combining cohorts
from various international sites support the notion that, compared to FE, GE phenotypes
have the strongest association with common genetic variation as a greater number of loci
are detected with increasing sample size [8,9]. One possible explanation for the paucity
of positive findings in FE is heterogeneity introduced by inclusion of cases with known
symptomatic causes (arterio-venous malformation, tumor, infection or trauma), as examined in most prior studies [5,6,8,9]. These patients likely harbor genetic risk factors that
are different than patients with idiopathic epilepsy and may dilute statistical power or
introduce other confounds. Patients with FE in the Philadelphia Cohort were only included
if they had no evidence for a symptomatic cause of their epilepsy.
Lack of replication of specific GWAS signals between independent cohorts remains
a problem in the field of epilepsy research. Thus far, the SCN1A locus is the most replicated
genetic risk factor found in epilepsy. It is a known causative factor in rare Mendelian
epilepsies, as well as a risk factor in common epilepsies [8,9]. The PADI findings in our
study are not reproduced at genome-wide significance levels in the larger meta-analyses
performed thus far [8,9]. Heterogeneity of cohorts collected from different parts of the world
likely contributes to this lack of replication at genome-wide levels. Thus, increasing sample
size may not always increase power for specific signals, as important variations may be
diluted when large heterogeneous populations are combined for analysis. In general,
replication of SNP variations that reach genome-wide significance from prior published
epilepsy GWAS have not been systematically studied in independent cohorts. While
the ILAE continues to pool cohorts to create larger sample sizes for continued GWAS
analysis, attempts to replicate prior findings in independent cohorts could help identify
true positive findings. Replication could be conducted with less stringent requirements
for claiming statistical significance, as correction for multiple testing is greatly reduced
when specific markers are tested compared with a genome-wide analysis. It is possible that
rare mutations in PADI4 or PADI6 are driving a synthetic association in our independent
cohort as the PADI loci do not appear to be genome-wide significant in larger meta-analyses
with other cohorts from around the world. Next generation sequencing of whole exomes
from patients in our cohort would allow testing of the possibility that our reported results
represent a synthetic association created by rare mutations in the Philadelphia Cohort.
In every GWAS, there are a number of sub-threshold associations detected that point to
genes participating in pathways that affect neurodevelopment or the electrical properties of
neurons. Prioritizing this list for analysis based on biological plausibility, brain expression
patterns and additional data linking genes to epilepsy phenotypes will identify additional
candidate molecules that warrant further study.
Here, we report a genome-wide significant association between GE and a locus on
chromosome 1 at 1p36.13 in the PADI4/PADI6 gene region. Three SNP markers in this
region reach genome-wide significance via METAL and six more SNPs have p-values
between 2.4 × 10−7 and 5.3 × 10−8 . These three SNPS also reach genome-wide significance
in the MANTRA analysis (Bayes ≥ 6.00), as well as two additional markers at Bayes = 5.99
and 5.96. Of interest is the fact that deletion of regions on 1p36 in humans leads to variable
clinical phenotypes, but the majority include epilepsy [16,17]. PADI4-PADI6 is in the critical
region of the 1p36 deletion syndromes; thus, our data point to this locus as potentially
involved in the epilepsy phenotype in these individuals.
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PADI4 encodes an enzyme that mediates the conversion of arginine to citrulline
as a post translational protein modification and is not able to convert free arginine to
citrulline [18]. Genetic variation in PADI4 has been associated with rheumatoid arthritis
through the utilization of GWAS [18]. It has been proposed that increased citrullination
of synovial proteins may alter their conformation and make them appear foreign, thereby
triggering an autoimmune response [19]. In support of this hypothesis, overexpression
of PADI4 activity leads to loss in myelin in mouse nervous tissue, and citrullination of
arginine residues in myelin proteins may induce autoantibody production [20,21]. More
important is documentation that PADI4 is expressed in both neurons and astrocytes of
the hippocampus and cortex in human brain, and may contribute to formation of autoantibodies in Alzheimer’s disease [22]. Autoantibodies have been reported previously
in patients with epilepsy, and over the past several decades, a substantial amount of literature on putative autoimmune defects in epilepsy has emerged [23]. It also is interesting
to note that histone modifications include arginine-to-citrulline conversion [24], and this
biochemical reaction decondenses chromatin and activates gene transcription, especially
for genes that are expressed by early pluripotent stem cell progenitors [25]. Alternatively,
arginine residues in histones are methylated as part of the epigenetic code, and conversion
to citrulline would eliminate this site of epigenetic regulation. Thus, histone citrullination
is an epigenetic process and it could be a mechanism that affects a wide variety of gene
targets, including some that mediate epileptogenesis.
We also found suggestive evidence for an association between GE and markers
on the X chromosome, with two markers near the TMEM47 gene reaching significance via
MANTRA (Bayes 6.39 and 6.23). TMEM47 encodes a transmembrane protein of unknown
function; thus, although the relationship to epileptogenesis is unclear, these results warrant
further study.
In addition to positive results in GE, our data also provide suggestive evidence for
several associations in FE, specifically in patients of African ancestry where we identified
weak signals within PIK3C3 and RANBP3, and weaker, single-marker signals in ASS1 and
MAP2K4P1. Although lone markers most likely represent false-positive results, ASS1 is
noteworthy in the context of our other findings because it encodes an enzyme that catalyzes
the penultimate step in arginine synthesis and is upstream of the PADI enzymatic pathway.
Nine linked markers with p-values just below genome-wide levels of significance in PIK3C3
make this gene of particular interest. PIK genes participate in autophagy and lysosomal
function [26]. Variations in PIK3C3 have been associated with bipolar and schizophrenia
in numerous studies [27]. The role of this gene in neurodevelopment is documented with
a case report of a deletion in the gene in a patient with a specific learning disability [28].
5. Conclusions
We identified a locus at 1p36.13 that is associated strongly with common forms of human GE and, taken together, our data suggest that PADI4 is the gene most likely to underlie
this signal. We document multiple linked markers at genome-wide levels of significance
by both METAL and MANTRA analyses. Additional markers of suggestive association
warrant further study in separate cohorts. Future progress anticipated in larger epilepsy
consortium projects will enable us to attempt replication of the results of the present study.
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